Interleukin-23: a promising therapeutic target in seronegative spondyloarthropathy.

Jonathan Sherlock, Daniel J Cua

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)
Original languageEnglish
Pages (from-to)445-448
JournalCurrent Opinion in Pharmacology
Volume13
Issue number3
Publication statusPublished - Jun 2013

Cite this